| Literature DB >> 28273649 |
Mangmang Sang1, Guangyan Du1, Jia Hao2, Linlin Wang2, Erwei Liu2, Yi Zhang2, Tao Wang2, Xiumei Gao1, Lifeng Han3.
Abstract
Xanthine oxidase (XOD), which could oxidize hypoxanthine to xanthine and then to uric acid, is a key enzyme in the pathogenesis of hyperuricemia and also a well-known target for the drug development to treat gout. In our study, the total alkaloids of Nelumbinis folium markedly inhibited XOD activity, with IC50 value being 3.313μg/mL. UHPLC-Q-TOF-MS and 3D docking analysis indicated that roemerine was a potential active ingredient. A response surface methodology combined with central composite design experiment was further developed and validated for the optimization of the reaction conditions between the total alkaloids of Nelumbinis folium and XOD, which could be considered as a meaningful research for the development of XOD inhibitor rapidly and sensitively.Entities:
Keywords: Central composite design; Nelumbinis folium; Response surface methodology; XOD inhibitor
Mesh:
Substances:
Year: 2017 PMID: 28273649 DOI: 10.1016/j.jpba.2017.02.048
Source DB: PubMed Journal: J Pharm Biomed Anal ISSN: 0731-7085 Impact factor: 3.935